WallStreetZenWallStreetZen

NASDAQ: ASMB
Assembly Biosciences Inc Stock

$1.11+0.15 (+15.63%)
Updated Jun 2, 2023
ASMB Price
$1.11
Fair Value Price
$2.19
Market Cap
$57.85M
52 Week Low
$0.77
52 Week High
$2.42
P/E
-0.61x
P/B
0.82x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$88.95M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.18
Operating Cash Flow
-$80M
Beta
1.1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ASMB Overview

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ASMB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ASMB ($1.11) is undervalued by 49.38% relative to our estimate of its Fair Value price of $2.19 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ASMB ($1.11) is significantly undervalued by 49.38% relative to our estimate of its Fair Value price of $2.19 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ASMB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ASMB due diligence checks available for Premium users.

Be the first to know about important ASMB news, forecast changes, insider trades & much more!

ASMB News

Valuation

ASMB fair value

Fair Value of ASMB stock based on Discounted Cash Flow (DCF)
Price
$1.11
Fair Value
$2.19
Undervalued by
49.38%
ASMB ($1.11) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ASMB ($1.11) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ASMB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ASMB price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.61x
Industry
11.51x
Market
52.69x

ASMB price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.82x
Industry
5.2x
ASMB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ASMB's financial health

Profit margin

Revenue
$0.0
Net Income
-$19.0M
Profit Margin
0%
ASMB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$83.1M
Liabilities
$12.8M
Debt to equity
0.18
ASMB's short-term assets ($79.74M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ASMB's short-term assets ($79.74M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ASMB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ASMB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$23.4M
Investing
$10.0M
Financing
$4.5M
ASMB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ASMB vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ASMB$57.85M+15.87%-0.61x0.82x
ADAG$57.53M+0.76%-0.72x0.69x
ARMP$58.19M+7.33%-1.35x2.59x
IOBT$58.21M+1.00%-0.82x0.47x
FIXX$56.93M-1.30%-0.45x0.37x

Assembly Biosciences Stock FAQ

What is Assembly Biosciences's quote symbol?

(NASDAQ: ASMB) Assembly Biosciences trades on the NASDAQ under the ticker symbol ASMB. Assembly Biosciences stock quotes can also be displayed as NASDAQ: ASMB.

If you're new to stock investing, here's how to buy Assembly Biosciences stock.

What is the 52 week high and low for Assembly Biosciences (NASDAQ: ASMB)?

(NASDAQ: ASMB) Assembly Biosciences's 52-week high was $2.42, and its 52-week low was $0.77. It is currently -54.13% from its 52-week high and 44.16% from its 52-week low.

How much is Assembly Biosciences stock worth today?

(NASDAQ: ASMB) Assembly Biosciences currently has 52,121,309 outstanding shares. With Assembly Biosciences stock trading at $1.11 per share, the total value of Assembly Biosciences stock (market capitalization) is $57.85M.

Assembly Biosciences stock was originally listed at a price of $31.50 in Dec 17, 2010. If you had invested in Assembly Biosciences stock at $31.50, your return over the last 12 years would have been -96.48%, for an annualized return of -24.33% (not including any dividends or dividend reinvestments).

How much is Assembly Biosciences's stock price per share?

(NASDAQ: ASMB) Assembly Biosciences stock price per share is $1.11 today (as of Jun 2, 2023).

What is Assembly Biosciences's Market Cap?

(NASDAQ: ASMB) Assembly Biosciences's market cap is $57.85M, as of Jun 6, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Assembly Biosciences's market cap is calculated by multiplying ASMB's current stock price of $1.11 by ASMB's total outstanding shares of 52,121,309.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.